<DOC>
	<DOCNO>NCT01825941</DOCNO>
	<brief_summary>Parenteral diphenhydramine commonly use adjuvant therapy acute migraine despite fact data support practice exist . The investigator propose randomize double blind study test hypothesis 50mg intravenous diphenhydramine , add standard migraine therapy , result great rate sustain headache relief standard migraine therapy alone . For study , standard migraine therapy 10mg intravenous metoclopramide . Sustained headache relief define achieve headache level `` mild '' `` none '' within two hour maintain level `` mild '' `` none '' 48 hour . Patients present Montefiore emergency room ( Bronx , NY ) acute migraine approach participation . They screen medication contra-indications non-migraine etiology headache . The study randomize . Assignment conceal . Participants researcher blind . Efficacy outcomes adverse event assess every half hour two hour ED telephone 48 hour medication administration . A sample size calculation , base pilot data , reveal need 374 participant . An interim analysis perform 200 participant enrol goal assess lack conditional power .</brief_summary>
	<brief_title>Diphenhydramine Acute Migraine</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Diphenhydramine</mesh_term>
	<mesh_term>Metoclopramide</mesh_term>
	<mesh_term>Promethazine</mesh_term>
	<criteria>Acute migraine headache Present emergency room Bronx , NY treatment migraine headache Temperature &gt; 100.3 F Pheochromocytoma Seizure disorder Parkinson 's disease Use MAO inhibitor Use antirejection transplant medication Use potassium supplement Use pramlintide</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>migraine</keyword>
	<keyword>headache</keyword>
	<keyword>metoclopramide</keyword>
	<keyword>diphenhydramine</keyword>
</DOC>